litlas
ログインアカウント作成

Edward A. Stadtmauer

1992–2025 年に発表

140
論文数
31,055
被引用数
88
h 指数
131
i10 指数

被引用数

Edward A. Stadtmauer の年別被引用数1989 年: 被引用 1 件1991 年: 被引用 1 件1992 年: 被引用 1 件1993 年: 被引用 3 件1994 年: 被引用 7 件1995 年: 被引用 8 件1996 年: 被引用 12 件1997 年: 被引用 19 件1998 年: 被引用 10 件1999 年: 被引用 24 件2000 年: 被引用 29 件2001 年: 被引用 26 件2002 年: 被引用 50 件2003 年: 被引用 78 件2004 年: 被引用 66 件2005 年: 被引用 78 件2006 年: 被引用 125 件2007 年: 被引用 156 件2008 年: 被引用 184 件2009 年: 被引用 210 件2010 年: 被引用 247 件2011 年: 被引用 264 件2012 年: 被引用 174 件2013 年: 被引用 277 件2014 年: 被引用 258 件2015 年: 被引用 277 件2016 年: 被引用 266 件2017 年: 被引用 248 件2018 年: 被引用 245 件2019 年: 被引用 789 件2020 年: 被引用 1,021 件2021 年: 被引用 1,063 件2022 年: 被引用 847 件2023 年: 被引用 576 件2024 年: 被引用 1,061 件2025 年: 被引用 547 件2026 年: 被引用 18 件1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,810 件、この内訳の 31.3%中国: 引用元論文 870 件、この内訳の 7.1%ドイツ: 引用元論文 834 件、この内訳の 6.8%イギリス: 引用元論文 676 件、この内訳の 5.6%イタリア: 引用元論文 595 件、この内訳の 4.9%フランス: 引用元論文 497 件、この内訳の 4.1%スペイン: 引用元論文 455 件、この内訳の 3.7%カナダ: 引用元論文 385 件、この内訳の 3.2%オランダ: 引用元論文 369 件、この内訳の 3%オーストラリア: 引用元論文 309 件、この内訳の 2.5%スイス: 引用元論文 262 件、この内訳の 2.2%日本: 引用元論文 220 件、この内訳の 1.8%
0%31.3%その他 23.8%

機関

分野

  • Medicine76.3%
  • Biochemistry, Genetics and Molecular Biology15.1%
  • Immunology and Microbiology5.8%
  • Economics, Econometrics and Finance1%
  • Engineering0.3%
  • Neuroscience0.2%
  • その他1.3%

トピック

  • CAR-T cell therapy research10.8%
  • Multiple Myeloma Research and Treatments8.1%
  • Protein Degradation and Inhibitors4.3%
  • Immunotherapy and Immune Responses3.8%
  • Immune Cell Function and Interaction3.3%
  • Virus-based gene therapy research3%
  • その他66.7%

共著者

全論文

検索で開く
  1. CRISPR-engineered T cells in patients with refractory cancer

    著者: Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis, Adam D. Cohen, Kristy Weber, Eric Lancaster, Patricia Mangan, Irina Kulikovskaya, Minnal Gupta, Fang Chen, Lifeng Tian, Vanessa Gonzalez, Jun Xu, In-Young Jung, J. Joseph Melenhorst, Gabriela Plesa, Joanne Shea, Tina Matlawski, Amanda Cervini, Avery L. Gaymon, Stephanie Desjardins, Anne Lamontagne, January Salas-McKee, Andrew D. Fesnak, Donald L. Siegel, Bruce L. Levine, Julie K. Jadlowsky, Regina M. Young, Anne Chew, Wei‐Ting Hwang, Elizabeth O. Hexner, Beatriz M. Carreno, Christopher L. Nobles, Frederic D. Bushman, Kevin R. Parker, Yanyan Qi, Ansuman T. Satpathy, Howard Y. Chang, Yangbing Zhao, Simon F. Lacey, Carl H. June - Science 2020 被引用: 1,484

  2. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

    著者: Guido Ghilardi, Joseph A. Fraietta, James N. Gerson, Vivianna M. Van Deerlin, Jennifer J.D. Morrissette, Gabriel C. Caponetti, Luca Paruzzo, Jaryse Harris, Elise A. Chong, Sandra P. Susanibar-Adaniya, Jakub Svoboda, Sunita D. Nasta, Ositadimma Ugwuanyi, Daniel J. Landsburg, Eugenio Fardella, Adam Waxman, Emeline R. Chong, Vrutti Patel, Raymone Pajarillo, Irina Kulikovskaya, David Lieberman, Adam D. Cohen, Bruce L. Levine, Edward A. Stadtmauer, Noelle V. Frey, Dan T. Vogl, Elizabeth O. Hexner, Stefan K. Barta, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Carl H. June, Marco Ruella - Nature Medicine 2024 被引用: 256

  3. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

    著者: Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer, J. Joseph Melenhorst, Simon F. Lacey, Eric Lancaster, Dan T. Vogl, Brendan M. Weiss, Karen Dengel, Annemarie Nelson, Gabriela Plesa, Fang Chen, Megan M. Davis, Wei‐Ting Hwang, Regina M. Young, Jennifer L. Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L. Siegel, Bruce L. Levine, Carl H. June, Michael C. Milone - Journal of Clinical Investigation 2019 被引用: 790

  4. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

    著者: Gerald P. Linette, Edward A. Stadtmauer, Marcela V. Maus, Aaron P. Rapoport, Bruce L. Levine, Lyndsey Emery, Leslie A. Litzky, Adam Bagg, Beatriz M. Carreno, Patrick J. Cimino, Gwendolyn Binder-Scholl, Dominic Smethurst, Andrew B. Gerry, Nick Pumphrey, Alan Bennett, Joanna E. Brewer, Joseph Dukes, Jane Harper, Helen K. Tayton-Martin, Bent K. Jakobsen, Namir J. Hassan, Michael Kalos, Carl H. June - Blood 2013 被引用: 1,163

  5. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

    著者: Connor A. Tsuchida, Nadav Brandes, Raymund Bueno, Marena Trinidad, Thomas Mazumder, Bingfei Yu, Byungjin Hwang, Christopher Chang, Jamin Liu, Yang Sun, Caitlin R. Hopkins, Kevin R. Parker, Yanyan Qi, Laura Hofman, Ansuman T. Satpathy, Edward A. Stadtmauer, J.H.D. Cate, Justin Eyquem, Joseph A. Fraietta, Carl H. June, Howard Y. Chang, Chun Ye, Jennifer A. Doudna - Cell 2023 被引用: 196

  6. NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

    著者: Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn Binder-Scholl, Olga Goloubeva, Dan T. Vogl, Simon F. Lacey, Ashraf Badros, Alfred L. Garfall, Brendan M. Weiss, Jeffrey Finklestein, Irina Kulikovskaya, Sanjoy K. Sinha, Shari S. Kronsberg, Minnal Gupta, Sarah Bond, Luca Melchiori, Joanna E. Brewer, Alan Bennett, Andrew B. Gerry, Nicholas J. Pumphrey, Daniel Williams, Helen K Tayton- Martin, Lilliam Ribeiro, Tom Holdich, Saul Yanovich, Nancy M. Hardy, Jean A. Yared, Naseem Kerr, Sunita Philip, Sandra Westphal, Don L. Siegel, Bruce L. Levine, Bent K. Jakobsen, Michael Kalos, Carl H. June - Nature Medicine 2015 被引用: 848

  7. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

    著者: Brian Cameron, Andrew B. Gerry, Joseph Dukes, Jane Harper, Vivekanandan Kannan, Frayne Bianchi, Francis Grand, Joanna E. Brewer, Minnal Gupta, Gabriela Plesa, Giovanna Bossi, Annelise Vuidepot, Alex S. Powlesland, Alison Legg, Katherine J. Adams, Alan Bennett, Nicholas J. Pumphrey, Daniel Williams, Gwendolyn Binder-Scholl, Irina Kulikovskaya, Bruce L. Levine, James L. Riley, Angel Varela‐Rohena, Edward A. Stadtmauer, Aaron P. Rapoport, Gerald P. Linette, Carl H. June, Namir J. Hassan, Michael Kalos, Bent K. Jakobsen - Science Translational Medicine 2013 被引用: 677

  8. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

    著者: Noopur Raje, Elias Anaissie, Shaji Kumar, Sagar Lonial, Thomas G Martin, Morie A. Gertz, Amrita Krishnan, Parameswaran Hari, Heinz Ludwig, Elizabeth O’Donnell, Andrew J. Yee, Jonathan L. Kaufman, Adam D. Cohen, Laurent Garderet, Ashutosh F Wechalekar, Evangelos Terpos, Navin Khatry, Rubén Niesvizky, Qing Yi, Douglas Joshua, Tapan Saikia, Nelson Leung, Monika Engelhardt, Mohamad Mothy, Andrew R. Branagan, Ajai Chari, Tony Reiman, Brea Lipe, Joshua Richter, S. Vincent Rajkumar, Jesús F. San Miguel, Kenneth C. Anderson, Edward A. Stadtmauer, Rao Prabhala, Phillip McCarthy, Nikhil C. Munshi - The Lancet Haematology 2022 被引用: 191

  9. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

    著者: Alfred L. Garfall, Ehren K. Dancy, Adam D. Cohen, Wei‐Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L. Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, J. Joseph Melenhorst - Blood Advances 2019 被引用: 229

  10. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation

    著者: Adriana Bastidas, Javier de la Serna, Mohamed El Idrissi, Lidia Oostvogels, Philippe Quittet, Javier López‐Jiménez, Filiz Vural, David Pohlreich, Tsila Zuckerman, Nicolas C. Issa, Gianluca Gaïdano, Je‐Jung Lee, Sunil Abhyankar, Carlos Solano, Jaime Pérez de Oteyza, Michael J. Satlin, Stefan Schwartz, Magda Campins, Alberto Rocci, Carlos Vallejo Llamas, Dong‐Gun Lee, Sen Mui Tan, Anna Johnston, Andrew Grigg, Michael J. Boeckh, Laura Cámpora, Marta López‐Fauqued, Thomas C. Heineman, Edward A. Stadtmauer, Keith M. Sullivan, for the ZOE-HSCT Study Group Collaborators - JAMA 2019 被引用: 257

  11. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma

    著者: Kavita M. Dhodapkar, Adam D. Cohen, Akhilesh Kaushal, Alfred L. Garfall, Renee Julia Manalo, Allison R. Carr, Samuel S. McCachren, Edward A. Stadtmauer, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Michael C. Milone, Madhav V. Dhodapkar - Blood Cancer Discovery 2022 被引用: 108

  12. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia

    著者: Noelle V. Frey, Saar Gill, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W. Loren, Jakub Svoboda, Edward A. Stadtmauer, Daniel J. Landsburg, Anthony R. Mato, Bruce L. Levine, Simon F. Lacey, J. Joseph Melenhorst, Elizabeth Veloso, Avery L. Gaymon, Edward Pequignot, Xinhe Shan, Wei‐Ting Hwang, Carl H. June, David L. Porter - Journal of Clinical Oncology 2020 被引用: 185

  13. Combined autophagy and proteasome inhibition

    著者: Dan T. Vogl, Edward A. Stadtmauer, Kay-See Tan, Daniel F. Heitjan, Lisa E. Davis, Laura Pontiggia, Reshma Rangwala, Shengfu Piao, Yunyoung C Chang, Emma C. Scott, Thomas Paul, Charles W. Nichols, David Porter, Janeen Kaplan, G. Mallon, James E. Bradner, Ravi K. Amaravadi - Autophagy 2014 被引用: 373

  14. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

    著者: Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei‐Ting Hwang, Dan T. Vogl, Adam Waxman, Simon F. Lacey, Vanessa Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V. Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer - Blood Cancer Discovery 2022 被引用: 76

  15. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

    著者: Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Dina Ben‐Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Jesús F. San Miguel, Joan Bladé, Mario Boccadoro, Jamie Cavenagh, William S. Dalton, Anthony Boral, Dixie Esseltine, Jane Porter, David P. Schenkein, Kenneth C. Anderson - New England Journal of Medicine 2005 被引用: 2,493

  16. Cytokine-mediated CAR T therapy resistance in AML

    著者: Anand Bhagwat, Leonel Torres, Olga Shestova, Maksim Shestov, Patrick Mellors, Han R Fisher, Saamia Farooki, Benjamin F. Frost, Michael R. Loken, Avery L. Gaymon, Diane Frazee, Walter Rogal, Noelle V. Frey, Elizabeth O. Hexner, Selina M. Luger, Alison W. Loren, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Edward A. Stadtmauer, Jennifer L. Brogdon, Joseph A. Fraietta, Wei‐Ting Hwang, Don L. Siegel, Gabriela Plesa, Richard Aplenc, David L. Porter, Carl H. June, Saar Gill - Nature Medicine 2024 被引用: 81

  17. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    著者: Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G. Richardson, Thierry Façon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, Al‐Ola Abdallah, Ashraf Badros, Stefan Knop, Edward A. Stadtmauer, Yiming Cheng, Michael Amatangelo, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Teresa Peluso, Niels W.C.J. van de Donk - The Lancet Haematology 2022 被引用: 92

  18. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

    著者: Alfred L. Garfall, Marcela V. Maus, Wei‐Ting Hwang, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Zhaohui Zheng, Dan T. Vogl, Adam D. Cohen, Brendan M. Weiss, Karen Dengel, Naseem Kerr, Adam Bagg, Bruce L. Levine, Carl H. June, Edward A. Stadtmauer - New England Journal of Medicine 2015 被引用: 638

  19. Carfilzomib-Associated Cardiovascular Adverse Events

    著者: Adam Waxman, Suparna C. Clasen, Wei‐Ting Hwang, Alfred L. Garfall, Dan T. Vogl, Joseph R. Carver, Rupal O’Quinn, Adam D. Cohen, Edward A. Stadtmauer, Bonnie Ky, Brendan M. Weiss - JAMA Oncology 2017 被引用: 276

  20. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

    著者: Andrew Matthews, Alexander E. Perl, Selina M. Luger, Alison W. Loren, Saar Gill, David L. Porter, Daria V. Babushok, Ivan Maillard, Martin Carroll, Noelle V. Frey, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, Edward A. Stadtmauer, Vikram R. Paralkar, Ximena Jordan Bruno, Wei‐Ting Hwang, David M. Margolis, Keith W. Pratz - Blood Advances 2022 被引用: 100

  21. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

    著者: Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, David D. Hurd, Hani Hassoun, Paul G. Richardson, Sergio Giralt, Edward A. Stadtmauer, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie S. Callander, Koen van Besien, Teresa Gentile, Luis Isola, Richard T. Maziarz, Don A. Gabriel, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H. Qazilbash, Denise Levitan, Brian McClune, Robert Schlossman, Vera Hárs, John Postiglione, Chen Jiang, Elizabeth Bennett, Susan Barry, Linda R. Bressler, Michael E. Kelly, Michele Seiler, Cara A. Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker - New England Journal of Medicine 2012 被引用: 1,143

  22. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma

    著者: Edward A. Stadtmauer, Thomas Faitg, Daniel E. Lowther, Ashraf Badros, Karen Chagin, Karen Dengel, Malini Iyengar, Luca Melchiori, Jean‐Marc Navenot, Elliot Norry, Trupti Trivedi, Ruoxi Wang, Gwendolyn K. Binder, Rafael G. Amado, Aaron P. Rapoport - Blood Advances 2019 被引用: 88

  23. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

    著者: Julie K. Jadlowsky, Elizabeth O. Hexner, Amy Marshall, Stephan A. Grupp, Noelle V. Frey, James L. Riley, Elizabeth Veloso, Holly McConville, Walter Rogal, Cory Czuczman, Wei‐Ting Hwang, Yimei Li, Rachel Leskowitz, Olivia Farrelly, Jayashree Karar, Shannon Christensen, Julie S. Barber-Rotenberg, Avery L. Gaymon, Naomi Aronson, Wendy Bernstein, J. Joseph Melenhorst, Aoife M. Roche, J.K. Everett, Sonja A. Zolnoski, Alexander McFarland, Shantan Reddy, Angelina Petrichenko, Emma J. Cook, Carole Lee, Vanessa Gonzalez, Kathleen A. Alexander, Irina Kulikovskaya, Ángel Ramírez-Fernández, Janna Minehart, Marco Ruella, Saar Gill, Stephen J. Schuster, Adam D. Cohen, Alfred L. Garfall, Payal D. Shah, David L. Porter, Shannon L. Maude, Bruce L. Levine, Don L. Siegel, Anne Chew, S.J. McKenna, Lester Lledo, Megan M. Davis, Gabriela Plesa, Friederike Herbst, Edward A. Stadtmauer, Pablo Tebas, Amanda M. DiNofia, A. Haas, Naomi B. Haas, Regina M. Myers, Donald M. O’Rourke, Jakub Svoboda, János L. Tanyi, Richard Aplenc, Jeffrey M. Jacobson, Andrew H. Ko, Roger B. Cohen, Carl H. June, Frederic D. Bushman, Joseph A. Fraietta - Nature Medicine 2025 被引用: 71

  24. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

    著者: Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer, Elihu H. Estey, Bob Löwenberg, Hervé Dombret, Chatchada Karanes, Matthias Theobald, John M. Bennett, Matthew L. Sherman, Mark S. Berger, Catharine B. Eten, Michael R. Loken, Jacques J. M. van Dongen, Irwin D. Bernstein, Frederick R. Appelbaum, for the Mylotarg Study Group - Journal of Clinical Oncology 2001 被引用: 893